

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number

10/526091

Filing Date

February 23, 2005

First Named Inventor

Stefano et al.

Art Unit

1655

Examiner Name

Randall Winston

Attorney Docket Number

R1381-200US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]


Examiner Signature	<i>[Signature]</i>	Date Considered	<i>8/22/08</i>
-----------------------	--------------------	--------------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/526,091	
			Filing Date	02/23/2005	
			First Named Inventor	Stefano et al.	
			Group Art Unit	1685	
			Examiner Name	LANDAU WINSTON	
Sheet	1	of	2	Attorney Docket Number	R1381-200US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cita No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
a		Bilfinger et al., "Pharmacological Evidence for Anandamide Amidase in Human Cardiac and Vascular Tissues," International Journal of Cardiology, vol. 64, Suppl. 1, pp. S15 – S22, 1998.	
~		Bilfinger et al., "Human Aortocoronary Grafts and Nitric Oxide Release: Relationship to Pulsatile Pressure," Annals of Thoracic Surgery, vol. 69, pp. 480 – 485, 2000.	
~		Deutsch et al., "Production and Physiological Actions of Anandamide in the Vasculature of the Rat Kidney," Journal of Clinical Investigation, vol. 100, no. 6, pp. 1538 – 1546, 1997.	
e		Fimiani et al., "Opiate, Cannabinoid, and Eicosanoid Signaling Converges on Common Intracellular Pathways Nitric Oxide Coupling," Prostaglandins and Other Lipid Mediators, vol. 57, pp. 23 – 34, 1999.	
✓		Fimiani et al., "Morphine and Anandamide Stimulate Intracellular Calcium Transients in Human Arterial Endothelial Cells: Coupling to Nitric Oxide Release," Cellular Signaling, vol. 11, no. 3, pp. 189 – 193, 1999.	
✓		Magazine et al., "Morphine-Induced Conformational Changes in Human Monocytes, Granulocytes, and Endothelial Cells and in Invertebrate Immunocytes and Microglia are Mediated by Nitric Oxide ¹ ," Journal of Immunology, vol. 156, pp. 4845 – 4850, 1996.	
✓		Prevot et al., "Estradiol Coupling to Endothelial Nitric Oxide Stimulates Gonadotropin-Releasing Hormone Release from Rat Median Eminence Via a Membrane Receptor," Endocrinology, vol. 140, no. 2, pp. 652 – 659, 1999.	
✓		Prevot et al., "Morphine and Anandamide Coupling to Nitric Oxide Stimulates GnRH and CRF Release from Rat Median Eminence: Neurovascular Regulation," Brain Research, Vol. 790, pp. 236 – 244, 1998.	
✓		Salzet et al., "Leech Immunocytes Contain Proopiomelanocortin: Nitric Oxide Mediates Hemolymph Proopiomelanocortin Processing ¹ ," Journal of Immunology, vol. 159, pp. 5400 – 5411, 1997.	
✓		Salzet et al., "Invertebrate Proenkephalin: δ Opioid Binding Sites in Leech Ganglia and Immunocytes," Brain Research, vol. 768, pp. 224 – 232, 1997.	
✓		Sonetti et al., "Microglia in Invertebrate Ganglia," Proc. Natl. Acad. Sci. USA, vol. 91, pp. 9180 – 9184, September 1994.	
~		Stefano, G. B., "Autoimmunovascular Regulation: Morphine and Anandamide Stimulated Nitric Oxide Release," Journal of Neuroimmunology, vol. 83, pp. 70 – 76, 1998.	
✓		Stefano et al., "Stimulatory Effects of Opioid Neuropeptides on Locomotor Activity and Conformational Changes in Invertebrate and Human Immunocytes: Evidence for a Subtype of δ Receptor," Proc. Natl. Acad. Sci. USA, vol. 86 pp. 6307 – 6311, August 1989.	
✓		Stefano et al., "Presence of the $\mu 3$ Opiate Receptor in Endothelial Cells: Coupling to Nitric Oxide Production and Vasodilation," Journal of Biological Chemistry, vol. 270, no. 51, pp. 30290 – 30293, 1995.	

Examiner Signature		Date Considered	01/29/08
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/526 091
			Filing Date	02/23/2005
			First Named Inventor	Stefano et al.
			Group Art Unit	1689
			Examiner Name	Rebecca Winters
Sheet 2 of 2	Attorney Docket Number		R1381-200US	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
u		Stefano et al., "Evidence for the Involvement of Opioid Neuropeptides in the Adherence and Migration of Immunocompetent Invertebrate Hemocytes," Proc. Natl. Acad. Sci. USA, vol. 86, pp. 626 – 630, January 1989.	
u		Stefano et al., "Cannabinoid Receptors are Coupled to Nitric Oxide Release in Invertebrate Immunocytes, Microglia, and Human Monocytes," Journal of Biological Chemistry, vol. 271, no. 32, pp. 19238 – 19242, 1996.	
u		Stefano et al., "[D-Ala] ¹ Deltorphin I Binding and Pharmacological Evidence for a Special Subtype of δ Opioid Receptor on Human and Invertebrate Immune Cells," Proc. Natl. Acad. Sci. USA, vol. 89, pp. 9316 – 9320, October 1992.	
u		Stefano et al., "Mytilus Edulis Hemolymph Contains Pro-Opiomelanocortin: LPS and Morphine Stimulate Differential Processing," Molecular Brain Research, vol. 63, pp. 340 – 350, 1999.	
u		Stefano et al., "Enkefalin and Opioid Peptide Association in Invertebrates and Vertebrates: Immune Activation and Pain," Immunology Today, vol. 19, no. 6, pp. 265 – 268, June 1998.	
u		Stefano et al., "Morphine- and Anandamide-Stimulated Nitric Oxide Production Inhibits Presynaptic Dopamine Release," Brain Research, vol. 763, pp. 63 – 68, 1997.	
u		Stefano et al., "Invertebrate Opioid Precursors: Evolutionary Conservation and the Significance of Enzymatic Processing," International Reviews Cytol., vol. 187, pp. 261 – 186, 1999.	
u		Stefano et al., "Long-Term Exposure of Human Blood Vessels to HIV gp120, Morphine, and Anandamide Increases Endothelial Adhesion of Monocytes: Uncoupling of Nitric Oxide Release," Journal of Cardiovascular Pharmacology, vol. 31, pp. 862 – 868, 1998.	
u		Stefano et al., "Antagonism of LPS and IFN- γ Induction of iNOS in Human Saphenous Vein Endothelium by Morphine and Anandamide by Nitric Oxide Inhibition of Adenylate Cyclase," Journal of Cardiovascular Pharmacology, vol. 31, pp. 813 – 820, 1998.	
u		Stefano et al., "Macrophage Behavior Associated with Acute and Chronic Exposure to HIV GP120, Morphine and Anandamide: Endothelial Implications," International Journal of Cardiology, vol. 64, Suppl. 1, pp. S3 – S13, 1998.	
u		Stefano et al., "The Presence of the μ 3 Opiate Receptor in Invertebrate Neural Tissues," Comp. Biochem. Physiol., vol. 113C, no. 3, pp. 369 – 373, 1996.	
u		Bilfinger et al., "Direct Assessment and Diminished Production of Morphine Stimulated NO by Diabetic Endothelium from Saphenous Vein," Acta Pharmacologica Sinica, vol. 23, no. 2, pp. 97 – 102, Feb 2002.	
u		Stefano et al., "Cell-Surface Estrogen Receptors Mediate Calcium-Dependent Nitric Oxide Release in Human Endothelia," Circulation, vol. 101, pp. 1594 – 1597, 2000.	

Examiner Signature		Date Considered	01/17/09
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10526091
	Filing Date	2005-08-15
	First Named Inventor	George B. Stefano
	Art Unit	4614 1658
	Examiner Name	Unknown <i>Randal Winston</i>
	Attorney Docket Number	R1381-200US

U.S. PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S. PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button.							Add	
NON-PATENT LITERATURE DOCUMENTS							Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10526091
Filing Date		2005-08-15
First Named Inventor	George B. Stefano	
Art Unit	4614 1685	
Examiner Name	Unknown Randall Winslow	
Attorney Docket Number	R1381-200US	

✓	1	CHEN, S. et al., "Molluscicidal Saponins from Allium Vineale," Tetrahedron Letters, Vol. 28, No. 46 (1987), pp. 5603-5606.	<input type="checkbox"/>
✓	2	SURH, Y.-J. et al., "Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kB activation," Mutation Research 480-481 (2001), pp. 243-268.	<input type="checkbox"/>
✓	3	MURPHY, L.L. et al., "Ginseng, Sex Behavior, and Nitric Oxide," Ann. N.Y. Acad. Sci. 962 (2002), pp. 372-377.	<input type="checkbox"/>
✓	4	WANG, M. et al., "Immunomodulating activity of CVT-E002, a proprietary extract from North American ginseng (Panax quinquefolium)," Journal of Pharmacy and Pharmacology 53 (2001), pp. 1515-1523.	<input type="checkbox"/>
✓	5	KIM, H.-M. et al., "Activation of inducible nitric oxide synthase by Taraxacum officinale in mouse peritoneal macrophages," General Pharmacology 32 (1999), pp. 683-688.	<input type="checkbox"/>
✓	6	YUAN, C.-S. et al., "Panax Quinquefolium L. Inhibits Thrombin-Induced Endothelin Release In Vitro," American Journal of Chinese Medicine, Vol. XXVII, Nos. 3-4 (1999), pp. 331-338.	<input type="checkbox"/>
✓	7	BOVERIS, A. et al., "Effect of nitric oxide and plant antioxidants on microsomal content of lipid radicals," Biol. Res. 33 (2000), pp. 159-165.	<input type="checkbox"/>
✓	8	AUTHOR UNKNOWN, "Monograph: Taraxacum officinale," Alternative Medicine Review, Vol. 4, No. 2 (1999), pp. 112-114.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	2/1/08
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.